Cytotoxic T-Lymphocyte Associated Antigen 4 (CTLA4) Antibody

Este producto es parte de CTLA4 - cytotoxic T-lymphocyte associated protein 4
Product Graph
2834€ (1 mg)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
Cytotoxic T-Lymphocyte Associated Antigen 4 (CTLA4) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx342084
tested applications
SDS-PAGE

Description

Cytotoxic T-Lymphocyte Associated Antigen 4 (CTLA4) Antibody is a recombinant single domain antibody.

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Primary Antibodies
Immunogen Target
Cytotoxic T-Lymphocyte Associated Antigen 4 (CTLA4)
Reactivity
Human
Recommended Dilution
Optimal dilutions/concentrations should be determined by the end user.
Clonality
Monoclonal
Conjugation
Unconjugated
Isotype
sdAb
Clone ID
Q105
Purity
> 90% (SDS-PAGE)
Purification
Affinity purified.
Size 1
1 mg
Form
Liquid
Tested Applications
SDS-PAGE
Buffer
1X PBS containing 0.09% Sodium azide.
Availability
Shipped within 10-20 working days.
Storage
Aliquot and store at -20°C. Avoid repeated freeze-thaw cycles.
Dry Ice
No
Alias
Cytotoxic T-lymphocyte protein 4,CD,GSE,GRD4,ALPS5,CD152,Cytotoxic T-lymphocyte-associated antigen 4,CTLA-4,IDDM12,CELIAC3,
Background
Antibody anti-CTLA4
Status
RUO
Note
Concentration: > 1 mg/ml - 

Descripción

Cytotoxic T-lymphocyte associated protein 4 (CTLA-4), encoded by the CTLA4 gene on chromosome 2, is an essential immune checkpoint receptor primarily expressed on activated T cells and regulatory T cells (Tregs). CTLA-4 plays a crucial role in maintaining immune homeostasis by delivering inhibitory signals to downregulate T cell activation and proliferation. This receptor functions by binding to the ligands CD80 (B7-1) and CD86 (B7-2), which are expressed on antigen-presenting cells (APCs). By inhibiting excessive immune responses, CTLA-4 prevents autoimmunity and maintains immune tolerance to self-antigens. CTLA-4 is the first immune checkpoint to have been targeted for immunotherapy, exemplified by the development of the monoclonal antibody ipilimumab, which blocks CTLA-4 to boost anti-tumor immune responses. Given its significance in regulating immune responses, CTLA-4 is a focus of research in fields ranging from oncology to autoimmune disorders.

Related Products

EM0062

Mouse CTLA4(Cytotoxic T-Lymphocyte Associated Antigen 4) ELISA Kit

Ver Producto
FNab09937

anti- CTLA4 antibody

Ver Producto
P4807

Recombinant Human CTLA4

Ver Producto